



a

-

// : // :

SID

a :

FS EDSS

/ / % % :
EDSS (p< /) / /
% / (p< /)

β

a :

¹ MS: Multiple Sclerosis

² FS: Functional System

³ EDSS: Expanded disability status scale

(%)

()

(%)

/ /

/ ± /

/ ± /

/ ± /

/ ± /

(/ /)

(p< /)

EDSS

/ ± /

/ ± /

/ ± /

/ ± /

/ ± /

EDSS

(p< /)

...

= /

EDSS

p

/ ± /

EDSS

/ ± /

/ ± /

/ ± /

FS EDSS

EDSS

. ()

a


% /

. ()

%

(% /)

. ()



a

/

. ()

/

a

References:

- 1-Anderson. D.W, et al. Revised estimated of the prevalence of Multiple sclerosis in the United States. **Ann Neurology**. 1992; 31:333-336.
- 2-Freedman M, et al. Dose dependent clinical and MRI efficacy of IFN β -1 α in MS. **Ann Neurology**, 1998; 44: 992A.
- 3-Jacobs L, et al. Intramuscular IFN β -1 α therapy initiated during a first demyelinating event in MS.**Ann Neurol** 1996;39:285-294.
- 4-Keegan B.M. Multiple sclerosis. **In:** Johnson R.I, et al. Current therapy in neurologic disease. 6th ed. Mosby; 2002: 181.
- 5-Miller J.R. Multiple sclerosis. **In:** Rowland L.P. Merritt's textbook of neurology. 10th ed. Philadelphia: Lippincott; 2000; 773-796.
- 6-Olek J.M. and Dawson D.M. Multiple Sclerosis. **In:** Bradley W.G, et al. Neurology in clinical Practice. 4th Ed. New York: BH; 2004:1631-1664.
- 7-The IFN β Multiple Sclerosis study Group: Interferon beta is effective in RRMS.I. Clinical results of multicenter, randomized, double – blind, placebo- controlled trial. **Neurology**1993; 43: 655-661.
- 8- Web site: <http://www.msfcats.org>
- 9- Web site: <http://www.nmss.org>
- 10- Web site: <http://www.nlm.nih.gov>

Archive of SID